

CCPN SPAF Pocket Reference
January 2015
References:

1. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high risk patients with atrial fibrillation who are not adequately anticoagulated. *Stroke* 2009;40:235-240.
2. Cairns JA, Healey JS, Macle L, Mitchell LB, Verma A. The new canadian cardiovascular society algorithm for antithrombotic therapy of atrial fibrillation is appropriately based on current epidemiological data (Editorial). *Can J Cardiol* 2015;31:20-23
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. *JAMA* 2001;285:2864-2870.
4. Verma A, Cairns JA, Mitchell LB et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. *Can J Cardiol* 2014;30:1114-1130.
5. Lip GYH, Nieuwlaat R, Pisters R, Lane D, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The Euro Heart Survey on Atrial Fibrillation. *Chest* 2010;137:263-272.
6. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns JH, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. *Chest* 2010;138:1093-1100
7. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med* 2010;170:1433-41.
8. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circ* 2008;118:2029-2037.
9. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Arch Intern Med* 2007;167:239-245.
10. Hylek E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003;349:1019-1026.

11. Hart R et al. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Arch Intern Med* 2007;146:857-867.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1129-51.
13. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365(10):883-891.
14. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. *N Engl J Med* 2011;364:806-817.
15. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981-992.
16. Canadian Pharmacists Association. E-Therapeutics+:e-CPS: drug Monographs Aspirin[®], Available at www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m069600 [accessed December 5, 2010]
17. Canadian Pharmacists Association. E-Therapeutics+:e-CPS: drug Monographs Coumadin[®], Available at <https://www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m143200> [accessed December 5, 2010]
18. Holbrook A, Schulman S, Witt D et al. Evidence-based management of anticoagulant therapy. *Chest* 2012;141(2)(Suppl):e152S-e184S.
19. Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions involving warfarin: practice tool with practical management tips. *CPJ* 2011;144(1):21-25e.9. Also: <http://www.cpjournal.ca/doi/pdf/10.3821/1913-701X-144.1.21> Accessed May 15, 2012.
20. Pradaxa[®] Production Monograph, Boehringer Ingelheim Canada Ltd., Burlington, Toronto. Revision October 28, 2014.
21. Xarelto[®] Product Monograph, Bayer Inc, Toronto, Ontario. Revised July 10, 2014.
22. Eliquis[®] Production Monograph, Pfizer Canada Inc, Kirkland, Quebec and Bristol-Myers Squibb Canada, Montreal, Quebec. Revision November 4, 2014.
23. Moore KT, Vaidyanathan S, Damaraju CV, Fields LE. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when

administered orally or via nasogastric tube. *Clin Pharmacol in Drug Development* 2014;3(4):321-7.

24. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. *Br J Clin Pharmacol* 2013;75:476-87

25. Heidbuchel H, Verhamme P, Alings M et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. *Eur Heart J* 2013;34(27):2094-2106.

26. Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. *Am J Hematology* 2012;87: Suppl1 S141-5.

27. Schulman S and Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, when and how to switch. *Blood* 2012;119(3):3016-3023.

28. Advisory Committee Briefing Document: Pradaxa, Boehringer Ingelheim. August 27, 2010: pages 60-61.

29. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation* 2011;124:1573-1579.